摘要
目的:研究苦参素胶囊联合胸腺肽α-1治疗慢性乙型肝炎(CHB)的疗效和安全性。方法:60例CHB患者随机分为治疗组和对照组。治疗组(28例)口服苦参素胶囊,0.3g.次-1,3次.d-1,2mo后改为0.2g.次-1,3次.d-1;对照组(32例)肌肉注射干扰素α-2b500MU,1次.d-1,1mo后改为隔日1次。2组疗程均为24wk,治疗结束后随访48wk。比较2组的ALT复常率、HBV-DNA阴转率、HBeAg阴转率、HBeAg血清转换率。结果:治疗第12、24周时,治疗组的ALT复常率、HBV-DNA阴转率、HBeAg阴转率、HBeAg血清转换率与对照组比较,差异无统计学意义(P>0.05);治疗结束后第24、48周随访时,治疗组ALT复常率分别为64.3%和71.4%,对照组分别为34.4%和43.8%,2组比较差异有统计学意义(P<0.05);治疗组血清转换率分别为42.8%和46.4%,对照组分别为25.0%和21.9%,2组比较差异有统计学意义(P<0.05);治疗结束后第48周随访时,治疗组HBeAg阴转率为50.0%,对照组为25.0%,2组比较差异有统计学意义(P<0.05)。结论:苦参素胶囊联合胸腺肽α-1治疗CHB用药方便,能够明显抑制乙型肝炎病毒复制,且能持续应答,治疗期间安全性好。
OBJECTIVE： To observe the efficacy and safety of Oxymatrine capsule plus Thymosin α1 in the treatment of chronic hepatitis B （CHB） .METHODS： Of the total 60 patients with CHB, 28（trial group）were randomly assigned to receive Oxymatrine capsule orally （at a dose of 0.3g·time^-1 tid, 2mon later, reduced to 0.2g· time^-1tid）,and 32 （control group） to receive interferon α-2b500MU by intramuscular injection q.d but shifted to EOD 1 month later. All the patients were treated for 24wk and followed for additional 48wk.The ALT recovery rate, HBV-DNA negative changing rate, HBeAg negative changing rate, and seroconverslon rate were compared between the two groups.RESULTS： At 12 and 24 weeks＇ treatment, there were no significant differences between the 2 groups in ALT recovery rate, HBV-DNA negative changing rate, HBeAg negative changing rate, and seroconversion rate（P〉 0.05） .At 24 and 48 weeks＇ follow-up, ALT recovery rates of 64.3% vs. 71.4% achieved in the trial group, and 34.4% vs.43.8% in the control group, showing significant differences between the two groups（P〈0.05）, seroconversion rates of 42.8% vs. 46.4% achieved in the trial group, and 25.0% vs.21.9% in the control group, showing significant differences between two groups（P〈0.05）; At 48 weeks＇ follow-up, HBeAg negative changing rates of 50.0% achieved in trial group, and 25.0% in the control group, showing significant differences between the two groups （P 〈 0.05） .CONCLUSION： The combined therapy of Oxymatrine capsule plus Thymosin α- 1 was proved to be convenient and safe to use in treating chronic hepatitis B, and which showed significant inhibition on the replication of hepatitis B virus and to which patients had a sustained response.
出处
《中国药房》
CAS
CSCD
北大核心
2007年第24期1893-1894,共2页
China Pharmacy
关键词
慢性乙型肝炎
苦参素胶囊
胸腺肽Α-1
疗效观察
Chronic hepatitis B
Oxymatrine capsule
α- 1
Observation of curative efficacy .~
Thymosin a- 1
Observation of curative efficacy
